Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 1
2014 3
2016 1
2017 1
2018 3
2020 2
2021 4
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

16 results

Results by year

Filters applied: . Clear all
Page 1
Bispecific antibody platforms for cancer immunotherapy.
Lameris R, de Bruin RC, Schneiders FL, van Bergen en Henegouwen PM, Verheul HM, de Gruijl TD, van der Vliet HJ. Lameris R, et al. Crit Rev Oncol Hematol. 2014 Dec;92(3):153-65. doi: 10.1016/j.critrevonc.2014.08.003. Epub 2014 Aug 20. Crit Rev Oncol Hematol. 2014. PMID: 25195094 Review.
A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies.
Lameris R, Ruben JM, Iglesias-Guimarais V, de Jong M, Veth M, van de Bovenkamp FS, de Weerdt I, Kater AP, Zweegman S, Horbach S, Riedl T, Winograd B, Roovers RC, Adang AEP, de Gruijl TD, Parren PWHI, van der Vliet HJ. Lameris R, et al. Cell Rep Med. 2023 Mar 21;4(3):100961. doi: 10.1016/j.xcrm.2023.100961. Epub 2023 Mar 2. Cell Rep Med. 2023. PMID: 36868236 Free PMC article.
A single-domain bispecific antibody targeting CD1d and the NKT T-cell receptor induces a potent antitumor response.
Lameris R, Shahine A, Pellicci DG, Uldrich AP, Gras S, Le Nours J, Groen RWJ, Vree J, Reddiex SJJ, Quiñones-Parra SM, Richardson SK, Howell AR, Zweegman S, Godfrey DI, de Gruijl TD, Rossjohn J, van der Vliet HJ. Lameris R, et al. Nat Cancer. 2020 Nov;1(11):1054-1065. doi: 10.1038/s43018-020-00111-6. Epub 2020 Sep 14. Nat Cancer. 2020. PMID: 35122066
Improving CLL Vγ9Vδ2-T-cell fitness for cellular therapy by ex vivo activation and ibrutinib.
de Weerdt I, Hofland T, Lameris R, Endstra S, Jongejan A, Moerland PD, de Bruin RCG, Remmerswaal EBM, Ten Berge IJM, Liu N, van der Stelt M, Faber LM, Levin MD, Eldering E, Tonino SH, de Gruijl TD, van der Vliet HJ, Kater AP. de Weerdt I, et al. Among authors: lameris r. Blood. 2018 Nov 22;132(21):2260-2272. doi: 10.1182/blood-2017-12-822569. Epub 2018 Sep 13. Blood. 2018. PMID: 30213872 Free article.
Enhancement of NK Cell Antitumor Effector Functions Using a Bispecific Single Domain Antibody Targeting CD16 and the Epidermal Growth Factor Receptor.
Toffoli EC, Sheikhi A, Lameris R, King LA, van Vliet A, Walcheck B, Verheul HMW, Spanholtz J, Tuynman J, de Gruijl TD, van der Vliet HJ. Toffoli EC, et al. Among authors: lameris r. Cancers (Basel). 2021 Oct 29;13(21):5446. doi: 10.3390/cancers13215446. Cancers (Basel). 2021. PMID: 34771609 Free PMC article.
16 results